Soluble Guanylate Cyclase Stimulators and Activators
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
When Furchgott, Murad, and Ignarro were honored with the Nobel prize for the identification of nitric oxide (NO) in 1998, the therapeutic implications of this discovery could not be fully anticipated. This was due to the fact that available therapeutics like NO donors did not allow a constant and long-lasting cyclic guanylyl monophosphate (cGMP) stimulation and had a narrow therapeutic window. Now, 20 years later, the stimulator of soluble guanylate cyclase (sGC), riociguat, is on the market and is the only drug approved for the treatment of two forms of pulmonary hypertension (PAH/CTEPH), and a variety of other sGC stimulators and sGC activators are in preclinical and clinical development for additional indications. The discovery of sGC stimulators and sGC activators is a milestone in the field of NO/sGC/cGMP pharmacology. The sGC stimulators and sGC activators bind directly to reduced, heme-containing and oxidized, heme-free sGC, respectively, which results in an increase in cGMP production. The action of sGC stimulators at the heme-containing enzyme is independent of NO but is enhanced in the presence of NO whereas the sGC activators interact with the heme-free form of sGC. These highly innovative pharmacological principles of sGC stimulation and activation seem to have a very broad therapeutic potential. Therefore, in both academia and industry, intensive research and development efforts have been undertaken to fully exploit the therapeutic benefit of these new compound classes. Here we summarize the discovery of sGC stimulators and sGC activators and the current developments in both compound classes, including the mode of action, the chemical structures, and the genesis of the terminology and nomenclature. In addition, preclinical studies exploring multiple aspects of their in vitro, ex vivo, and in vivo pharmacology are reviewed, providing an overview of multiple potential applications. Finally, the clinical developments, investigating the treatment potential of these compounds in various diseases like heart failure, diabetic kidney disease, fibrotic diseases, and hypertension, are reported. In summary, sGC stimulators and sGC activators have a unique mode of action with a broad treatment potential in cardiovascular diseases and beyond. Graphical Abstract
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000066 · Cited by 4,347
A Novel Paradigm for Heart Failure With Preserved Ejection Fraction
Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.092 · Cited by 3,564 · cited 1×
“…treatment, an evolving understanding of the disease suggests that microvascular inflammation resulting in cardiac and systemic endothelial dysfunction may be a common underlying pathophysiology, highlighting the potential pharmacologic utility of sGC stimulators (Paulus and Tschope 2013).”
BackgroundRiociguat for the treatment of pulmonary arterial hypertension
Ghofrani, H.-A., Galiè, N., Grimminger, F., Grünig, E., Humbert, M., Jing, Z.-C., Keogh, A. M., Langleben, D., Kilama, M. O., Fritsch, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209655 · Cited by 1,346
A Specific Chemical Difference Between the Globins of Normal Human and Sickle-Cell Anæmia Hæmoglobin
INGRAM, V. M. (1956) · Nature · doi:10.1038/178792a0 · Cited by 896 · cited 1×
“Sickle cell disease (SCD) is an inherited blood disorder resulting from an allele of the hemoglobin beta gene that results in sickling of red blood cells (Ingram 1956).”
BackgroundStrategies to increase nitric oxide signalling in cardiovascular disease
Lundberg, J. O., Gladwin, M. T., & Weitzberg, E. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4623 · Cited by 576 · cited 1×
“…channels, and phosphodiesterases, making the NO/sGC/cGMP signaling a central vasoprotective signaling pathway (Lucas et al. 2000; Feil et al. 2003; Lundberg et al. 2015). sGC is a key signal-transduction enzyme in the cardiovascular system, and many cardiovascular diseases, such as hypertension,…”
BackgroundStructure and Regulation of Soluble Guanylate Cyclase
Derbyshire, E. R., & Marletta, M. A. (2012) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-050410-100030 · Cited by 466
Hypertension: A Harbinger of Stroke and Dementia
Faraco, G., & Iadecola, C. (2013) · Hypertension · doi:10.1161/hypertensionaha.113.01063 · Cited by 367 · cited 1×
“In addition, NO and sGC regulate local blood flow in the CNS in response to neuronal activity through a process known as functional hyperemia (Faraco and Iadecola 2013).”
BackgroundPieske, B., Maggioni, A. P., Lam, C. S. P., Pieske-Kraigher, E., Filippatos, G., Butler, J., Ponikowski, P., Shah, S. J., Solomon, S. D., Scalise, A.-V., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehw593 · Cited by 366 · cited 1×
“In the SOCRATESPRESERVED study (NCT01951638), no significant effect on NT-proBNP was observed but there was an improvement in quality of life scores (Pieske et al. 2017; Filippatos et al. 2017).”
BackgroundCytochrome b5 Reductase 3 Modulates Soluble Guanylate Cyclase Redox State and cGMP Signaling
Rahaman, M. M., Nguyen, A. T., Miller, M. P., Hahn, S. A., Sparacino-Watkins, C., Jobbagy, S., Carew, N. T., Cantu-Medellin, N., Wood, K. C., Baty, C. J., et al. (2017) · Circulation Research · doi:10.1161/circresaha.117.310705 · Cited by 92 · cited 3×
“Oxidative stress is associated with several cardiovascular diseases and is characterized by increased formation of reactive oxygen species (ROS) (Ritchie et al. 2017).”
BackgroundInfluentialGladwin, M. T. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29807 · Cited by 85 · cited 2×
“This therapeutic principle may preferentially dilate diseased versus normal blood vessels and therefore have far-reaching implications for the clinical use of sGC activators as unique diagnostic tools and innovative vascular therapy (Armitage et al. 2009; Stasch et al. 2006; Gladwin 2006).”
BackgroundMethodThoonen, R., Cauwels, A., Decaluwe, K., Geschka, S., Tainsh, R. E., Delanghe, J., Hochepied, T., De Cauwer, L., Rogge, E., Voet, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms9482 · Cited by 77
Self-citationGhosh, A., & Stuehr, D. J. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6690 · Cited by 19 · cited 1×
“Moreover, associations with other mechanisms of sGC regulation have been described, such as membrane association and binding to the chaperone CCTη or heat shock protein 90 (HSP90) (Erdmann et al. 2013; Ghosh and Stuehr 2017).”
BackgroundSharina, I. G., & Martin, E. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6687 · Cited by 19 · cited 2×
“In addition, sGC transcription and the stability of sGC mRNA are also affected by oxidative stress (Sharina and Martin 2017).”
Background
Metadata
- Authors
- Sandner, P., Zimmer, D. P., Milne, G. T., Follmann, M., Hobbs, A., & Stasch, J.-P.
- Venue
- Handbook of Experimental Pharmacology
- Publisher
- Springer International Publishing
- Published
- 2018
- Volume
- 264
- Pages
- 355-394
- ISSN
- 0171-2004 (ISSN-L)
- 1865-0325
- OpenAlex
- W2913885036
- Cited by
- 180
- References
- 14
- FWCI
- 17.29
- Type
- book chapter
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.